Prelude prioritizes SMARCA2 and CDK9, partners with AbCellera on ADCs, reports Q3 net loss $30.6M

Prelude Therapeutics Inc

2023-Q3 EPS reported -$1.55

Q3 net loss $30.6M ($0.45/share); cash at $230.5M; cash runway into 2026.
Prioritizing PRT3789 (SMARCA2 degrader) and PRT2527 (CDK9 inhibitor) for continued development.
Discontinuation of MCL-1 (PRT1419) and CDK4/6 (PRT3645) programs; seeking partners for PRT3645.
Entered partnership with AbCellera to develop precision ADCs using SMARCA payloads.
Expects initial Phase 1 data for SMARCA2 and CDK9 in mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.82

Prelude Therapeutics Inc reported financial results for the three months ended September 30, 2023.

Period: the three months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 1, 2023, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended September 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-057481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.